January 6, 2026

Dear Rett Syndrome Community,

We are writing to share an update on Taysha's clinical trials of TSHA-102, our investigational gene therapy for Rett syndrome. Below is a summary of the latest information.

Key Updates

- The **first patient** was dosed in the **REVEAL Pivotal Study** in the fourth quarter of 2025, and enrollment continues across multiple clinical trial sites.
- Taysha reached **further written alignment with the U.S. Food & Drug Administration (FDA) on a study for younger girls.** Additional details on the **ASPIRE Study** are provided below.
- **All participants** in both the REVEAL Pivotal Study and the ASPIRE Study are expected to be **dosed by the second quarter of 2026.**
- **Longer-term safety and efficacy data** from Part A of the REVEAL Study (Phase 1/2) is expected to be shared in the **first half of 2026.**

Overview of Taysha's Clinical Trials Investigating TSHA-102

TSHA-102 is an investigational gene therapy given through an intrathecal injection in the lumbar region of the spine (spinal tap), a minimally invasive procedure that delivers the therapy directly into cerebrospinal fluid.

The REVEAL Pivotal Study

- The REVEAL Pivotal Study is testing the efficacy and safety of TSHA-102 ($1x10^{15}$ total vector genomes) in **15 girls and young women aged 6 to under 22 years** with typical Rett syndrome who are in a developmental plateau, a stage where gains in certain milestones are very rare.
- The **primary endpoint** in the study will measure whether participants gain or regain at least one of 28 important developmental milestones in areas such as hand use (fine motor), mobility (gross motor) and communication, after receiving the study treatment.
- The study includes an **interim analysis** that will evaluate the data collected at the six-month post-treatment timepoint, which could help accelerate discussions with the FDA to support potential approval.

The ASPIRE Study

- The ASPIRE Study will test the safety and preliminary efficacy of TSHA-102 in **three young girls aged 2 to under 4 years** with typical Rett syndrome who are in earlier stages of development. The dose being studied is the same as in the REVEAL Pivotal Study ($1x10^{15}$ total vector genomes), adjusted to account for the smaller brain volume in children aged 2 to under 4 years.
- Data collected from ASPIRE will contribute to Taysha's submission to regulators to help support the potential future approval of TSHA-102 for patients aged 2 years and older.

For More Information

- **REVEAL Pivotal Study** (ages 6 to under 22 years): sites and contact information are listed here: https://clinicaltrials.gov/study/NCT05606614. Additional sites will be added.
- **ASPIRE Study** (ages 2 to under 4 years): site information will be posted to ClinicalTrials.gov once available.

If you have any questions, please email us at **patientaffairs@tayshagtx.com**. We truly appreciate your continued partnership and look forward to sharing more updates with you soon.

Sincerely,
The Taysha Patient Affairs Team